Abcellera Biologics, Inc. (ABCL)
NASDAQ:ABCL
Want to see ABCL full AI Analyst Report?
ABCL Stock Chart & Stats
$4.01
-$0.28(-8.54%)
At close: 4:00 PM EST
$4.01
-$0.28(-8.54%)
Day’s Range― - ―
52-Week Range$1.97 - $6.52
Previous CloseN/A
Volume1.71M
Average Volume (3M)8.27M
Market Cap
$1.59B
Enterprise Value$1.65B
Total Cash (Recent Filing)$504.73M
Total Debt (Recent Filing)$140.18M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding305,375,400
10 Day Avg. Volume9,611,063
30 Day Avg. Volume8,269,230
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)0.90
Price to Sales (P/S)13.60
P/FCF Ratio-5.87
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue20.84
Enterprise Value/Gross Profit26.36
Enterprise Value/Ebitda-9.45
Forecast
1Y Price Target
$9.40Price Target Upside134.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$33.21M
Bulls Say, Bears Say
Bulls Say
Clinical ValidationPositive proof-of-concept data for ABCL635 could validate the strategic shift toward internally developed candidates and materially reduce clinical development risk in investor assessments.
Commercial OpportunityStrong willingness from key opinion leaders to prescribe a safe, self‑administered subcutaneous antibody implies a sizable addressable market among patients who cannot take hormonal therapy and supports high commercial upside if efficacy is demonstrated.
Financial FlexibilityA solid cash position, supported by licensing revenues and a patent settlement, provides runway for internal programs and enhances the company's ability to pursue partnerships and milestone-driven upside.
Bears Say
Analyst Conflict RiskA disclosed conflict of interest at a research firm may undermine confidence in analyst reports and increase stock volatility due to perceived bias in published assessments.
Clinical Benchmark RiskUpcoming clinical results will be compared to established therapies, creating a demanding efficacy hurdle that could hurt valuation if the data falls short of market expectations.
Revenue Transition RiskManagement's move to prioritize the internal pipeline is expected to reduce research fee revenue, creating near-term revenue headwinds before new program milestones can generate offsetting income.
AbCellera Biologics News
ABCL FAQ
What was Abcellera Biologics, Inc.’s price range in the past 12 months?
Abcellera Biologics, Inc. lowest stock price was $1.97 and its highest was $6.51 in the past 12 months.
What is Abcellera Biologics, Inc.’s market cap?
Abcellera Biologics, Inc.’s market cap is $1.59B.
When is Abcellera Biologics, Inc.’s upcoming earnings report date?
Abcellera Biologics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 71 days.
How were Abcellera Biologics, Inc.’s earnings last quarter?
Abcellera Biologics, Inc. released its earnings results on May 11, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.171 by $0.031.
Is Abcellera Biologics, Inc. overvalued?
According to Wall Street analysts Abcellera Biologics, Inc.’s price is currently Undervalued.
Does Abcellera Biologics, Inc. pay dividends?
Abcellera Biologics, Inc. does not currently pay dividends.
What is Abcellera Biologics, Inc.’s EPS estimate?
Abcellera Biologics, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Abcellera Biologics, Inc. have?
Abcellera Biologics, Inc. has 305,375,400 shares outstanding.
What happened to Abcellera Biologics, Inc.’s price movement after its last earnings report?
Abcellera Biologics, Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.171. Following the earnings report the stock price went down -5.714%.
Which hedge fund is a major shareholder of Abcellera Biologics, Inc.?
Currently, no hedge funds are holding shares in ABCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.40 (134.41% Upside)
$9.40 (134.41% Upside)
Blogger Sentiment
Neutral
ABCL Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $952.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
168.52%
12-Months-Change
Fundamentals
Return on Equity
-14.22%
Trailing 12-Months
Asset Growth
-2.76%
Trailing 12-Months
Company Description
Abcellera Biologics, Inc.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
ABCL Company Deck
ABCL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive clinical and financial picture: compelling interim Phase I data for ABCL635 (favorable tolerability, strong PK/PD and sustained target engagement) with a clear near-term Phase II catalyst (Q3 2026), expanding pipeline progress, and a robust liquidity position (~$655M available including government funding). Headwinds include continued quarterly losses (~$43M), modest current revenue (~$8M) with expected declines in partner-derived research fees, a small potential tolerability signal at the highest dose (900 mg), blinded MAD data limiting full visibility, and remaining scientific/efficacy risk until Phase II readout. Overall, positives (clinical momentum, liquidity, and pipeline cadence) outweigh the negatives, but the company remains dependent on upcoming Phase II and other near-term milestones.View all ABCL earnings summariesABCL Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
ABCL Stock 12 Month Forecast
Average Price Target
$9.40
▲(134.41% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Arcus Biosciences
―
Dianthus Therapeutics
―
Edgewise Therapeutics
―
Structure Therapeutics, Inc. Sponsored ADR
―
Ownership Overview
40.88% Insiders
4.67% Mutual Funds
19.86% Other Institutional Investors
33.24% Public Companies and Individual Investors